+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of Cardiac Contractility Modulation CCM therapy in patients with heart failure who have a left ventricular ejection fraction LVEF between 40% and 70%. The study is a randomized, quadruple-blind, sham-controlled trial conducted at multiple centers across the US and internationally. It includes two parts with distinct scientific goals the first part focuses on functional capacity and health status, while the second part focuses on clinical outcomes. Participants will have the OPTIMIZER Smart Mini System implanted. They will be randomly assigned in a 21 ratio to either receive active CCM therapy CCM ON or a sham treatment with the device turned off CCM OFF during the first 18 months. CCM therapy involves seven one-hour treatment phases spaced evenly over 24 hours daily. After the 18-month blinded phase, those in the sham group will have CCM therapy turned on for the remainder of the study. The trial will enroll about 1500 subjects in total and follow them for up to 18 months or longer through both parts. Participants will undergo screening and baseline tests before implantation. Researchers will monitor their functional capacity using the 6-minute walk test and assess health status with the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety will be tracked by recording device- or procedure-related complications within the first year. Clinical outcomes including mortality and morbidity will be evaluated over 18 months. Follow-up visits and data collection will continue through the study duration to assess these measures and the long-term safety and effectiveness of CCM therapy.

Age: 18Years +All GendersPhase Not Applicable
67 locations
P

Actively Recruiting

Researchers are evaluating the effect of dalcetrapib on cardiovascular risk in people recently hospitalized for acute coronary syndrome ACS who have a specific genetic profile AA genotype. This phase 3, randomized, double-blind, placebo-controlled study focuses on adults aged 45 years and older, aiming to assess the time to first occurrence of fatal or non-fatal myocardial infarction over an average of 30 months from randomization. The study will continue until around 200 participants experience a primary event, or until stopped at an interim analysis. Participants will be randomly assigned to receive either dalcetrapib 600 mg daily, two 300 mg tablets or matching placebo tablets once daily. Screening includes genetic testing for the AA genotype using a specialized Genotype Assay Test. Enrollment can begin during hospitalization or after discharge, but randomization must occur within 12 weeks of the ACS event. After randomization, follow-up visits will be virtual when possible or in clinic every three months until the study ends. Assessments will continue every three months for participants who stop the study medication early. Participants will undergo medical history review and genetic testing before enrollment. During the study, researchers will monitor cardiovascular events such as heart attacks and strokes through regular assessments every three months. Safety evaluations and collection of study endpoints will continue for the duration of participation, which may last approximately 30 months or until the study stops. This includes ongoing monitoring for adverse effects and overall health status.

Age: 45Years +All GendersPhase 3
231 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.

Age: 18Years +All GendersPhase 4
149 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the MagicTouch14 Sirolimus-coated balloon compared to plain old balloon angioplasty POBA in treating coronary in-stent restenosis ISR, which occurs when previously placed drug-eluting stents become narrowed again. This prospective, randomized, two-arm, single-blind superiority trial involves subjects with prior drug-eluting stent implantation who require percutaneous coronary intervention PCI for ISR. The study aims to establish whether the MagicTouch device improves treatment outcomes for coronary artery lesions. Participants will be randomly assigned in a 21 ratio to receive either the MagicTouch Sirolimus-coated balloon or POBA during PCI to treat the ISR lesion. Before treatment, patients undergo medical history review, physical exams, lab tests, and ECGs. Blood samples will be collected before and after the procedure to assess cardiac biomarkers such as troponin T. During hospitalization, patients receive clinical assessments and ECGs biomarker samples are taken at specified intervals to monitor heart muscle injury. After discharge, patients have follow-up visits at 30 days, 6 months, 12 months, and annually up to 5 years, which include ECGs, blood tests, medication reviews, and adverse event monitoring. Angiograms performed within the first year will be reviewed by a blinded core lab to evaluate lesion status. Participants will be involved in scheduled clinical assessments, laboratory testing, and imaging evaluations to track heart function and treatment outcomes. Researchers will measure the primary outcome of target lesion failure at 12 months and multiple secondary outcomes related to cardiovascular events, revascularization, mortality, myocardial infarction, bleeding, and procedural success up to 5 years. The study includes safety monitoring through biomarker analysis and ECGs during hospitalization and detailed follow-up visits extending through 60 months post-procedure to assess long-term effects.

Age: 18Years - 110YearsAll GendersPhase Not Applicable
28 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the MagicTouchTM Sirolimus-Coated Balloon in treating small blood vessels 2.75 mm or less in diameter in patients with coronary artery disease. This multicenter, randomized, single-blind study aims to compare this drug-coated balloon with drug-eluting stents in patients needing percutaneous coronary intervention PCI for lesions in small native coronary arteries. The trial plans to enroll about 1605 subjects across up to 50 sites in North America, with additional sites in Europe and South America. Participants will be randomly assigned in a 21 ratio to receive either the MagicTouchTM sirolimus-coated balloon or a drug-eluting stent approved by the FDA either Everolimus or Zotarolimus eluting stents. The treatment targets a single lesion in a major coronary artery or side branch, with lesion size limits between less than 2.75 mm and up to 34 mm in length. Lesion preparation must be successful prior to treatment. The study includes a detailed follow-up period assessing outcomes up to 60 months, focusing on safety and performance measures. During the study, participants will provide medical history and undergo physical exams, lab tests, and a 12-lead ECG within 7 days before the procedure. Women of childbearing potential will have pregnancy tests before treatment. Patient-reported angina symptoms will be tracked using the Seattle Angina Questionnaire at baseline, 30 days, 6 months, and 12 months, with further follow-up visits to monitor target lesion failure and other cardiovascular events for up to five years. The primary outcome is target lesion failure at 12 months after intervention.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
24 locations
T

Actively Recruiting

This research aims to provide additional information on the LimFlow System for treating late-stage chronic limb-threatening ischemia in patients who cannot have standard endovascular or surgical limb salvage procedures. The study focuses on using a minimally invasive approach to create an arteriovenous connection in the below-the-knee blood vessels to arterialize the pedal veins and improve blood flow in the affected limb. Participants will be treated with the LimFlow Stent Graft System, which creates an arteriovenous fistula in the target limb through a percutaneous, endovascular procedure. This single-arm, multi-center study involves one treatment group receiving this device to assess its use and effects in this patient population. During the study, participants will undergo assessments including wound healing evaluations, limb salvage status, and patency of the treated vessels at multiple time points up to 12 months. Researchers will monitor amputation-free survival at 6 months as the primary outcome and assess other clinical and procedural outcomes such as technical success, wound size reduction, and safety measures. Participants will be followed for ongoing evaluation of treatment impact and safety.

Age: 18Years - 95YearsAll GendersPhase Not Applicable
30 locations